» Articles » PMID: 23144292

Serum γ-glutamyltransferase and the Risk of Heart Failure in Men and Women in Finland

Overview
Journal Heart
Date 2012 Nov 13
PMID 23144292
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To evaluate the association of serum γ-glutamyltransferase (GGT) levels with heart failure (HF) risk in the Finnish population.

Design: Prospective population-based cohort study.

Setting: The present study, which is a part of FINRISK study, was carried out in Finland. Subject study cohorts included 18 353 Finnish men and 19 726 women who were 25-74 years of age and free of HF at baseline. Main outcome measures HF (636 men and 445 women) during a mean follow-up of 14.5 years.

Results: Baseline measurement of different levels of serum GGT was used to predict incident HF. The multivariable-adjusted (age, sex, study area, study year, smoking, education, alcohol consumption, physical activity, valvular heart disease, body mass index (BMI), systolic blood pressure, total cholesterol at baseline, myocardial infarction and diabetes at baseline and during follow-up) HRs of HF at five GGT groups (using the 25th, 50th, 75th and 90th percentiles) were 1.00, 1.16 (95% CI: 0.97 to 1.38), 1.20 (1.00 to 1.45), 1.29 (1.04 to 1.60) and 1.82 (1.45 to 2.29) (P(trend)<0.001). Stratification by smoking status, alcohol consumption and BMI gave similar results, while stronger association was observed among subjects aged <60 years (P(trend)=0.001) compared with subjects 60+ years of age (P(trend)=0.173).

Conclusions: Moderate to high levels of serum GGT (from the 50th to the 90th percentiles) were significantly associated with incident HF in men and women in Finland, and the predictive power was stronger in subjects aged <60 years.

Citing Articles

Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.

Sandireddy R, Sakthivel S, Gupta P, Behari J, Tripathi M, Singh B Front Cell Dev Biol. 2024; 12:1433857.

PMID: 39086662 PMC: 11289778. DOI: 10.3389/fcell.2024.1433857.


Non-Alcoholic Fatty Liver Disease as an Emerging Risk Factor for Heart Failure.

Inciardi R, Mantovani A, Targher G Curr Heart Fail Rep. 2023; 20(4):308-319.

PMID: 37402108 PMC: 10421789. DOI: 10.1007/s11897-023-00613-1.


Gamma-glutamyl transferase and risk of all-cause and disease-specific mortality: a nationwide cohort study.

Cho E, Jeong S, Chung G, Yoo J, Cho Y, Lee K Sci Rep. 2023; 13(1):1751.

PMID: 36720971 PMC: 9888340. DOI: 10.1038/s41598-022-25970-0.


Prognostic impact of albumin-bilirubin score on the prediction of in-hospital mortality in patients with heart failure: a retrospective cohort study.

Han S, Wang C, Tong F, Li Y, Li Z, Sun Z BMJ Open. 2022; 12(1):e049325.

PMID: 34983753 PMC: 8728421. DOI: 10.1136/bmjopen-2021-049325.


Gamma-Glutamyl Transferase (γ-GT) - an old dog with new tricks?.

Brennan P, Dillon J, Tapper E Liver Int. 2021; 42(1):9-15.

PMID: 34775657 PMC: 11165564. DOI: 10.1111/liv.15099.